Identification of hypermethylated CpG sites mapped to LIFR as specific diagnostic biomarkers of colon cancer  

作　　者：Ruizhi Chang Ganxun Li Guan-nan Jin Bixiang Zhang Ze-yang Ding 

机构地区：[1]Department of Surgery and Hubei Key Laboratory of Hepatic-Pancreatic-Biliary Diseases,National Medical Center for Major Public Health Events,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430030,China [2]Present address:Department of Internal Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430077,China

出　　处：《Genes & Diseases》2025年第2期98-101,共4页基因与疾病(英文)

基　　金：supported by the National Nature Science Foundation of China (No.82273441,81874065);the National Basic Research Program of China (No.2020YFA0710700);the Knowledge Innovation Program of Wuhan-Shuguang Project (China) (No.2022020801020456);Tongji Hospital (HUST)Foundation for Excellent Young Scientist (China) (No.2020YQ05);the First Level of the Public Health Youth Top Talent Project of Hubei Province (China) (No.2022SCZ051).

摘　　要：Despite the improvement of programmatic screening,adjuvant chemotherapy,and curative resection,colon cancer,with increasing incidence and mortality rates,still poses a significant public health challenge as the third most commonly diagnosed and second most fatal cancer worldwide.1 The myriad of benefits,encompassing the improved survival rates,treatment outcomes,and cost efficiency,further underscore the criticality of early colon cancer diagnosis.

关 键 词：COLON cancer MORTALITY 

分 类 号：R73[医药卫生—肿瘤]